Andrew E. Aplin, PhD

Contact Dr. Aplin

233 South 10th Street
BLSB 522
Philadelphia, PA 19107

(215) 503-7296
(215) 923-9248 fax

Most Recent Peer-reviewed Publications

  1. Co-Targeting HGF/cMET Signaling with MEK Inhibitors in metastatic uveal melanoma
  2. An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma
  3. Triple jeopardy for people with albinism
  4. The melanoma field with dendritic roots
  5. The state of melanoma: challenges and opportunities
  6. Targeting mutant NRAS signaling pathways in melanoma
  7. Of Mice and melanoma: PDX system for modeling personalized medicine
  8. Welcome to the New Year!
  9. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma
  10. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization
  11. Fibroblast-derived neuregulin 1 promotes Compensatory ErbB3 receptor signaling in mutant BRAF melanoma
  12. PAX3 and FOXD3 promote CXCR4 expression in melanoma
  13. ErbB3-ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas
  14. Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
  15. Game of isoforms: PI3K β-sparing inhibitor is coming
  16. The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox
  17. The value of thesis advisers
  18. Animal experimentation - questioned again!
  19. The value of thesis advisers
  20. NF-κB regulation of c-FLIP promotes TNFα-mediated RAF inhibitor resistance in melanoma